CoChat

Developments and Challenges for mAb-Based Therapeutics

Open access
Goswami, Sumit, Wang, Wei, Arakawa, Tsutomu, Ohtake, Satoshi · 2013 · Antibodies

The DOI matches its Crossref record; 311 of the 323 references it cites were found in a registry or an index.

Abstract

The continuous increase in the number of approved monoclonal antibody (mAb)-based therapy suggests that mAbs, and their derivatives, will continue to be the focus of the biotherapeutics industry for years to come. Although vast improvements in our capability to manufacture, characterize, and stabilize mAbs have been achieved, there are still challenges to be overcome. These include analytical and stabilization approaches associated with the development of high concentration mAb formulations. In addition, several mAb-based modalities are under development, including antibody drug conjugates (ADCs), fusion proteins, and bispecific antibodies (bsAbs), all designed to overcome the limitations encountered with mAb therapy. The current status of their development, with emphasis on manufacturing challenges as well as preliminary clinical results, will be reviewed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/antib2030452

Cites

311 of 311 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Illustrative comparison of the structure of ADC to those of fusion proteins. Note that although these effector molecules are shown to be fused to either the N- or C-terminus, they can also be fused to the other terminus. Though ADCs are shown to be linked to the C-terminus of antibodies or their fragments, they can also be linked to other functional groups, e.g., the N-terminus or side chains, by in vitro chemical reaction.
Figure 1 Illustrative comparison of the structure of ADC to those of fusion proteins. Note that although these effector molecules are shown to be fused to either the N- or C-terminus, they can also be fused to the other terminus. Though ADCs are shown to be linked to the C-terminus of antibodies or their fragments, they can also be linked to other functional groups, e.g., the N-terminus or side chains, by in vitro chemical reaction.CC-BY · From the PDF
Figure 2 Illustration of the mechanism of mAb-effector fusion protein of a prodrug. The mAb is directed towards tumor-associated antigens and the enzyme is delivered to the tumor cell, within which the prodrug is cleaved, releasing the cytotoxic drug.
Figure 2 Illustration of the mechanism of mAb-effector fusion protein of a prodrug. The mAb is directed towards tumor-associated antigens and the enzyme is delivered to the tumor cell, within which the prodrug is cleaved, releasing the cytotoxic drug.CC-BY · From the PDF
Figure 3 Illustration of a tetrameric fusion complex (anti-transferrin receptor (TfR) antibody/avidin fusion). Avidin (○) is fused to the C-terminus of the antibody.
Figure 3 Illustration of a tetrameric fusion complex (anti-transferrin receptor (TfR) antibody/avidin fusion). Avidin (○) is fused to the C-terminus of the antibody.CC-BY · From the PDF
Figure 4 Illustration of various Fc-fusion proteins: ( A ) construct of extracellular domain of receptors (ExR) fused to the N-terminus of Fc, ( B ) FIX (coagulation factor IX)-Fc monomer comprising one functional FIX and two Fc domains, and ( C ) Fc fusion of the peptide, romiplostin/Nplate®, that contains two tandem repeats of the peptide. Fc is depicted as long rectangles and the peptide as short rectangles. These three constructs form dimers through the Fc domain.
Figure 4 Illustration of various Fc-fusion proteins: ( A ) construct of extracellular domain of receptors (ExR) fused to the N-terminus of Fc, ( B ) FIX (coagulation factor IX)-Fc monomer comprising one functional FIX and two Fc domains, and ( C ) Fc fusion of the peptide, romiplostin/Nplate®, that contains two tandem repeats of the peptide. Fc is depicted as long rectangles and the peptide as short rectangles. These three constructs form dimers through the Fc domain.CC-BY · From the PDF
Figure 5 Illustration of various bispecific antibodies, including bispecific T-cell engager (BiTE®), Dual-Affinity Re-Targeting (DART TM ), tetravalent bispecific recombinant antibody (TandAb®), and Immune mobilizing mTCR Against Cancer (ImmTAC). Figure from May et al . [225].
Figure 5 Illustration of various bispecific antibodies, including bispecific T-cell engager (BiTE®), Dual-Affinity Re-Targeting (DART TM ), tetravalent bispecific recombinant antibody (TandAb®), and Immune mobilizing mTCR Against Cancer (ImmTAC). Figure from May et al . [225].CC-BY · From the PDF
Figure 6 Schematic representation of various antibody formats, including the intact IgG molecule alongside various representations of antibody fragments. Figure from Holliger and Hudson [273].
Figure 6 Schematic representation of various antibody formats, including the intact IgG molecule alongside various representations of antibody fragments. Figure from Holliger and Hudson [273].CC-BY · From the PDF

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 311 references

Research works printed but not linked: 4

  1. Pearlman, R., and Wang, Y.J. (1996). Formulation, Characterization, and Stability of Protein Drugs, Plenum Press.
  2. Hershenson, F.J.S. (2010). Formulation and Process Development Strategies for Manufacturing Biopharmaceuticals, John Wiley & Sons, Inc.
  3. Scherer, T., Kanai, S., Liu, J., and Shire, S. (, 2007). Characterization of monoclonal antibodies at high concentrations by light scattering. Proceedings of AAPS National Biotechnology Conference, San Diego, CA, USA.
  4. Brock, T.D. (1998). Milestones in Microbiology; 1556–1940, ASM Press.

Cited by

See all 155

Metadata

Authors
Goswami, S., Wang, W., Arakawa, T., & Ohtake, S.
Affiliations
  • Pfizer (United States) (US)
  • Alliance Protein Laboratories (United States) (US)
Corresponding author
Arakawa, Tsutomu
Venue
Antibodies
Publisher
MDPI AG
Published
2013-08-16
Volume
2
Issue
3
Pages
452-500
ISSN
2073-4468 (ISSN-L)
OpenAlex
W2033785641
Cited by
144
References
323
Citations by year
2026: 5 · 2025: 17 · 2024: 10 · 2023: 9 · 2022: 8 · 2021: 14 · 2020: 18 · 2019: 10 · 2018: 14 · 2017: 12 · 2016: 12 · 2015: 10 · 2014: 4 · 2013: 1
FWCI
6.98
Type
journal article
Language
en
Open access
Locations
  • Antibodies (publishedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein purification and stability
  • Life Sciences › Immunology and Microbiology › Immunology › Biosimilars and Bioanalytical Methods
Keywords
monoclonal antibodies, biologic therapy, antibody-drug conjugates, bispecific antibodies, fusion protein, high-concentration formulations, antibody stabilization, antibody production

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Developments and Challenges for mAb-Based Therapeutics. https://app.cochat.ai/papers/10.3390/antib2030452
The paper
Goswami, S., Wang, W., Arakawa, T., & Ohtake, S. (2013). Developments and Challenges for mAb-Based Therapeutics. Antibodies. https://doi.org/10.3390/antib2030452

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.